JNM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Deterding, T. A.
Right arrow Articles by Hoffman, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Deterding, T. A.
Right arrow Articles by Hoffman, J. M.
Journal of Nuclear Medicine Vol. 42 No. 2 376-381
© 2001 by Society of Nuclear Medicine

BASIC SCIENCE INVESTIGATIONS

Biodistribution and Radiation Dosimetry of the Dopamine Transporter Ligand [18F]FECNT

Todd A. Deterding, John R. Votaw, Chris K. Wang, Dennis Eshima, Lori Eshima, Robert Keil, Eugene Malveaux, Clinton D. Kilts, Mark M. Goodman and John M. Hoffman

Center for PET, Division of Nuclear Medicine, Department of Radiology, Emory University Hospital, Atlanta; and School of Mechanical Engineering, Georgia Institute of Technology, Atlanta, Georgia

18F-labeled 2 ß-carbomethoxy-3ß-(4-chlorophenyl)-8-(-2-fluoroethyl)nortropane ([18F]FECNT) is a recently developed dopamine transporter ligand with potential applications in patients with Parkinson’s disease and cocaine addiction. Methods: Estimates of the effective dose equivalent and doses for specific organs were made using biodistribution data from 16 Sprague-Dawley rats and nine rhesus monkeys. PET images from two rhesus monkeys were used to calculate the residence time for the basal ganglia. The computer program MIRDOSE3 was used to calculate the dosimetry according to the methodology recommended by MIRD. Results: The basal ganglia were the targeted tissues receiving the highest dose, 0.11 mGy/MBq (0.39 rad/mCi). The effective dose equivalent was 0.018 mSv/MBq (0.065 rem/mCi), and the effective dose was 0.016 mSv/MBq (0.058 rem/mCi). Conclusion: Our data show that a 185-MBq (5-mCi) injection of [18F]FECNT leads to an estimated effective dose of 3 mSv (0.3 rem) and an estimated dose to the target organ or tissue of 19.4 mGy (1.93 rad).

Key Words: dosimetry • dopamine transporter • [18F]FECNT




This article has been cited by other articles:


Home page
 J. Pharmacol. Exp. Ther.Home page
S. Chalon, H. Hall, W. Saba, L. Garreau, F. Dolle, C. Halldin, P. Emond, M. Bottlaender, J.-B. Deloye, J. Helfenbein, et al.
Pharmacological Characterization of (E)-N-(4-Fluorobut-2-enyl)-2beta-carbomethoxy-3beta-(4'-tolyl)nortropane (LBT-999) as a Highly Promising Fluorinated Ligand for the Dopamine Transporter
J. Pharmacol. Exp. Ther., April 1, 2006; 317(1): 147 - 152.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
M. R. Davis, J. R. Votaw, J. D. Bremner, M. G. Byas-Smith, T. L. Faber, R. J. Voll, J. M. Hoffman, S. T. Grafton, C. D. Kilts, and M. M. Goodman
Initial Human PET Imaging Studies with the Dopamine Transporter Ligand 18F-FECNT
J. Nucl. Med., June 1, 2003; 44(6): 855 - 861.
[Abstract] [Full Text] [PDF]

Home page
 JNMHome page
T. Tolvanen, K. Lehtio, J. Kulmala, V. Oikonen, O. Eskola, J. Bergman, and H. Minn
18F-Fluoroerythronitroimidazole Radiation Dosimetry in Cancer Studies
J. Nucl. Med., December 1, 2002; 43(12): 1674 - 1680.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
JOURNAL OF NUCLEAR MEDICINE TECHNOLOGY THE JOURNAL OF NUCLEAR MEDICINE
Copyright © 2001 by the Society of Nuclear Medicine.